GlassScriptPhysician profile
Amy Quinn
NPI 1417206657
$6,474.05
in general payments reported to CMS, 2019-2025
29 companies · $1,869 in 2025
The $1,869 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $458 · 2022: $532 · 2023: $2,051 · 2024: $1,563 · 2025: $1,869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,589 · Travel and Lodging: $894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,589.23 |
| Travel and Lodging | $894.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $1,164.95 | 2023 | Ha Minuteman G3-R |
| Saluda Medical Americas, INC. | $875.52 | 2024-2025 | Evoke |
| Boston Scientific Corporation | $748.32 | 2021-2025 | Wavewriter Alpha Prime 16, General - Pain Management, General - Therapies |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $618.83 | 2021-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $551.02 | 2021-2025 | Belbuca, Xtampza |
| Abbvie INC. | $473.68 | 2022-2025 | |
| Abbott Laboratories | $357.63 | 2022-2025 | Eterna, Proclaim |
| Globus Medical, INC. | $283.67 | 2025 | Senza |
| Pfizer INC. | $231.32 | 2023-2025 | |
| Lundbeck LLC | $123.46 | 2024-2025 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $121.71 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $113.87 | 2022 | |
| Grt US Holding, INC. | $108.78 | 2021-2022 | |
| Averitas Pharma INC. | $105.91 | 2023-2025 | Qutenza |
| Alkermes, INC. | $90.79 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Painteq LLC | $70.09 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $56.60 | 2025 | |
| Lilly USA, LLC | $55.45 | 2021-2023 | Emgality, Reyvow |
| Vertos Medical, INC. | $54.80 | 2023-2024 | Mild Device Kit |
| Allergan, INC. | $42.37 | 2022 | |
| Medline Industries LP | $37.03 | 2024 | Medline Industries, INC. |
| Mml US, INC. | $32.37 | 2023 | Reactiv8 |
| Amgen INC. | $31.38 | 2021-2022 | |
| Curonix LLC | $29.04 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Medtronic, INC. | $21.22 | 2022 | |
| Fidia Pharma USA INC. | $20.51 | 2025 | Hymovis, Triluron |
| Nevro Corp. | $20.38 | 2021 | |
| Zimmer Biomet Holdings, INC. | $17.15 | 2025 | Gel-One Cross-Linked Hyaluronate |
| Biodelivery Sciences International, INC. | $16.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Quinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.